{"id":175611,"name":"VIZIENT INC","slug":"vizient-inc","state":"TX","country":"United States of America","description":"Healthcare services company","totalSpending":1880000,"filings":32,"yearlySpending":[{"year":2018,"income":200000},{"year":2019,"income":240000},{"year":2020,"income":240000},{"year":2021,"income":240000},{"year":2022,"income":240000},{"year":2023,"income":240000},{"year":2024,"income":240000},{"year":2025,"income":240000}],"issues":[{"code":"HCR","display":"Health Issues"},{"code":"MMM","display":"Medicare/Medicaid"},{"code":"PHA","display":"Pharmacy"}],"firms":["MEHLMAN CONSULTING, INC."],"lobbyists":["DEAN ROSEN","LAUREN ARONSON","ALYENE MLINAR","CAITLIN VAN SANT"],"govEntities":["Health & Human Services, Dept of (HHS)","HOUSE OF REPRESENTATIVES","SENATE","Centers For Medicare and Medicaid Services (CMS)","Food & Drug Administration (FDA)","Office of the Vice President of the United States","White House Office","Office of Management & Budget (OMB)"],"sampleDescriptions":["Healthcare coverage; prescription drug costs; group purchasing issues.\n340B Drug Discount Program issues.","Healthcare coverage; prescription drug costs; group purchasing issues.\n340B Drug Discount Program issues.","Healthcare coverage; prescription drug costs; group purchasing issues.\n340B Drug Discount Program issues.\nDrug shortage issues.","Prescription drug pricing; Part B CAP program.","Healthcare coverage; prescription drug costs; group purchasing issues.\n340B Drug Discount Program issues.\nDrug shortage issues."]}